Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
A global view of the genetic basis of Alzheimer disease
C Reitz, MA Pericak-Vance, T Foroud… - Nature Reviews …, 2023 - nature.com
The risk of Alzheimer disease (AD) increases with age, family history and informative genetic
variants. Sadly, there is still no cure or means of prevention. As in other complex diseases …
variants. Sadly, there is still no cure or means of prevention. As in other complex diseases …
Development of Alzheimer's disease biomarkers: From CSF-to blood-based biomarkers
S Mankhong, S Kim, S Lee, HB Kwak, DH Park, KL Joa… - Biomedicines, 2022 - mdpi.com
In the 115 years since the discovery of Alzheimer's disease (AD), our knowledge, diagnosis,
and therapeutics have significantly improved. Biomarkers are the primary tools for clinical …
and therapeutics have significantly improved. Biomarkers are the primary tools for clinical …
Harmonization and standardization of biofluid‐based biomarker measurements for AT (N) classification in Alzheimer's disease
C Giangrande, V Delatour… - Alzheimer's & …, 2023 - Wiley Online Library
Fluid biomarkers are currently measured in cerebrospinal fluid and blood for Alzheimer's
disease diagnosis and are promising targets for drug development and for patients' follow …
disease diagnosis and are promising targets for drug development and for patients' follow …
Circulating biomarkers of inflammaging and Alzheimer's disease to track age-related trajectories of dementia: Can we develop a clinically relevant composite …
AM Abbatecola, A Giuliani, L Biscetti, L Scisciola… - Ageing Research …, 2024 - Elsevier
Alzheimer's disease (AD) is a rapidly growing global concern due to a consistent rise of the
prevalence of dementia which is mainly caused by the aging population worldwide. An early …
prevalence of dementia which is mainly caused by the aging population worldwide. An early …
Blood tests for Alzheimer's disease: increasing efforts to expand and diversify research participation is critical for widespread validation and acceptance
TK Karikari - Journal of Alzheimer's Disease, 2022 - content.iospress.com
The recent academic and commercial development, and regulatory approvals, of blood-
based Alzheimer's disease (AD) biomarkers are breakthrough developments of immense …
based Alzheimer's disease (AD) biomarkers are breakthrough developments of immense …
Moving Towards Ethical-Practical Recommendations for Alzheimer's Disease Prediction: Addressing Interindividual, Interprofessional, and Societal Aspects
S Schicktanz, Z Alpinar-Segawa… - Journal of …, 2024 - journals.sagepub.com
Biomarkers for predicting Alzheimer's disease (AD) are advancing and their implementation
in various healthcare systems is imminent. There is a need for ethical standards addressing …
in various healthcare systems is imminent. There is a need for ethical standards addressing …
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and …
BC Dickerson, A Atri, C Clevenger… - Alzheimer's & …, 2024 - Wiley Online Library
US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to
Alzheimer's disease (AD) or a related dementia (ADRD) are two decades old. This evidence …
Alzheimer's disease (AD) or a related dementia (ADRD) are two decades old. This evidence …
A novel automated Chemiluminescence method for detecting cerebrospinal fluid Amyloid-beta 1-42 and 1-40, total Tau and Phosphorylated-Tau: implications for …
M Arcaro, C Fenoglio, M Serpente, A Arighi… - Biomedicines, 2022 - mdpi.com
Recently, a fully automated instrument for the detection of the Cerebrospinal Fluid (CSF)
biomarker for Alzheimer's disease (AD)(low concentration of Amyloid-beta 42 (Aβ42), high …
biomarker for Alzheimer's disease (AD)(low concentration of Amyloid-beta 42 (Aβ42), high …
A pragmatic, data-driven method to determine cutoffs for CSF biomarkers of Alzheimer disease based on validation against PET imaging
Background and Objectives To elaborate a new algorithm to establish a standardized
method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the …
method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the …